HPV16 L1 - oral cancer risk screening gl
HPV 16 is one of the most aggressive HPV strains. Presence of antibodies against HPV16 indicate a 40-fold increased risk of developing oral cancer.
HPV16 L1 - oral cancer risk screening
HPV 16 is one of the most aggressive HPV strains.
Presence of antibodies against HPV16 indicate a 40-fold increased risk of developing oral cancer.
Oral cancer is twice as prevalent as cervical cancer yet has low awareness and no public screenings.
High levels of HPV Ab in people over 40 indicate an ongoing cancerogenesis.
German Ministry of Health guidelines recommend detection of HPV antibodies as a risk indicator.
Due to the low awareness of oral cancer, it is often first detected by the appearance of lesions, in the late stages of tumour progression. An early diagnosis increases the chances of survival, which is why oral cancer risk screening is critical as it gives the patient and doctor additional time and options to prevent the disease, or catch it in a more treatable stage. By testing HPV16 Ab levels present in the blood, Prevo-Check provides a valuable indication of the risks a person has of developing oral cancer. This is particularly relevant for the group most considered at risk; males over 50 years old who smoke and drink alcohol. If the results show high levels of antibodies, the person can take preventative steps or seek necessary treatment; get suspicious cells checked, visit a specialist doctor or dentist and ensure he/she has regular oral cavity inspections for the next couple of years.
Rapid test for the immunological detection of antibodies against HPV16 in whole blood and serum samples.
Can be used for both risk assessment and ongoing cancerogenesis.
Fast, easy to read result in just 15 minutes.